Age-dependent variation of fecal calprotectin in cystic fibrosis and healthy children

Millie Garg; Steven T Leach; Michael J Coffey; Tamarah Katz; Roxanne Strachan; Tamara Pang; Bronwen Needham; Kei Lui; Fathalla Ali; Andrew S Day; Laura Appleton; Vesal Moeeni; Adam Jaffe; Chee Y Ooi

doi:10.1016/j.jcf.2017.03.010

Age-dependent variation of fecal calprotectin in cystic fibrosis and healthy children

J Cyst Fibros. 2017 Sep;16(5):631-636. doi: 10.1016/j.jcf.2017.03.010. Epub 2017 Apr 14.

Authors

Millie Garg¹, Steven T Leach¹, Michael J Coffey¹, Tamarah Katz², Roxanne Strachan³, Tamara Pang¹, Bronwen Needham⁴, Kei Lui⁵, Fathalla Ali¹, Andrew S Day⁶, Laura Appleton⁶, Vesal Moeeni⁶, Adam Jaffe⁷, Chee Y Ooi⁸

Affiliations

¹ School of Women's and Children's Health, Medicine, The University of New South Wales, Sydney, New South Wales, Australia.
² Department of Nutrition and Dietetics, Sydney Children's Hospital, High Street, Randwick 2031, New South Wales, Australia.
³ Department of Respiratory Medicine, Sydney Children's Hospital, High Street, Randwick 2031, New South Wales, Australia.
⁴ Sydney Medical Program, The University of Sydney, Camperdown 2050, New South Wales, Australia.
⁵ School of Women's and Children's Health, Medicine, The University of New South Wales, Sydney, New South Wales, Australia; Department of Newborn Care, The Royal Hospital for Women, Barker Street, Randwick 2031, New South Wales, Australia.
⁶ Department of Pediatrics, University of Otago, 2 Riccarton Ave, Christchurch 8011, Canterbury, New Zealand.
⁷ School of Women's and Children's Health, Medicine, The University of New South Wales, Sydney, New South Wales, Australia; Department of Respiratory Medicine, Sydney Children's Hospital, High Street, Randwick 2031, New South Wales, Australia.
⁸ School of Women's and Children's Health, Medicine, The University of New South Wales, Sydney, New South Wales, Australia; Department of Gastroenterology, Sydney Children's Hospital, High Street, Randwick 2031, New South Wales, Australia. Electronic address: keith.ooi@unsw.edu.au.

PMID: 28416415
DOI: 10.1016/j.jcf.2017.03.010

Abstract

Background: Fecal calprotectin may be used as a non-invasive method to assess the effect of novel therapies on the gut in cystic fibrosis (CF).

Method: Stools from CF patients and healthy controls (HC) (0-10years old) were prospectively collected for evaluation of temporal trends.

Results: 130 CF samples (64 subjects) and 114 HC samples (101 subjects) were collected. Overall, fecal calprotectin levels were different in CF patients and HC from 0 to 10years (P=0.0002). Fecal calprotectin in CF was significantly lower than HC from 0 to 1years (P=0.03) and demonstrated an upward trajectory until 4years. From >4 to 10years calprotectin was consistently higher in CF patients compared with HC (P=0.007).

Conclusions: Fecal calprotectin levels in children with CF and HC were age-dependent and had distinct trajectories. Careful interpretation of calprotectin is required if used in drug trials for CF, particularly in children less than 4years old.

Keywords: Calprotectin; Cystic fibrosis; Gastrointestinal inflammation; Leukocyte L1 antigen complex; Pediatrics; S100 proteins.

MeSH terms

Age Factors
Biomarkers / analysis
Child
Child, Preschool
Cystic Fibrosis* / diagnosis
Cystic Fibrosis* / physiopathology
Feces*
Female
Humans
Infant
Infant, Newborn
Inflammation* / diagnosis
Inflammation* / etiology
Inflammation* / physiopathology
Intestinal Mucosa* / metabolism
Intestines* / physiopathology
Leukocyte L1 Antigen Complex / analysis*
Male
Reproducibility of Results

Substances

Biomarkers
Leukocyte L1 Antigen Complex